The S&P is over the magical 1,000 barrier and things are feeling exuberant in the stock markets again. But, could this just be a false start? It seems some pretty smart bloggers are starting to sound the “come back to earth bell.”  Here’s my run down of some of the best and most interesting articles I’ve read this week.

Edward Harrison of Credit Writedowns warns that consumer spending could be weak for years. Naked Capitalism echoes this sentiment and gives some reasons for why we should expect a pullback at some point in the near future. James Hamilton of EconBrowser asks us whether the glass is half empty or half full featuring two charts plotting our recent rebound vs. ...

Alexion: One-Drug Wonder Continues - How Long Can This Be Sustained? Soliris sales continues to grow in 1Q09Late last week, Alexion Pharmaceuticals, Inc. (ALXN) reported first quarter 2009 financial results. Soliris sales were in line with our expectation of $81.3 million -- up 78.1% y-o-y and 5% sequentially.Due to strong Soliris sales, Alexion has been enjoying profitability since the second quarter last year. In 1Q09, adjusted net income was $14.6 million, with diluted earnings per share (EPS) of $0.16. Excluding share-based expenses, Alexion achieved a net income of $22.5 million or EPS of $0.25 in 1Q09. First quarter net income and EPS were less than our estimate of $17.6 million and $0.19 per share due to higher R&D and SG&A expenses. Soliris (eculizumab) is a humanized monoclonal antibody complement inhibitor, which blocks cleavage of the C5 component of the complement ...

WallStNewsletters.com Full Monte contributor Chad Brand, aka. the Peridot Capitalist wrote last week about a company the Masters have been keeping a watch on, UnitedHealth Group Inc. (NYSE:UNH). Besides Warren Buffett buying more shares the stock has rallied 7% in the past three days and it is still less than $3 from its 52-week low. First off, be sure to check out Chad's article - Election Worries Have Put HMO Stocks Like United On Sale.  Chad had this to say: The combination of political risk and a recent acceleration in healthcare cost ...